These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28636433)

  • 1. Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.
    Gay CL; DeBenedette MA; Tcherepanova IY; Gamble A; Lewis WE; Cope AB; Kuruc JD; McGee KS; Kearney MF; Coffin JM; Archin NM; Hicks CB; Eron JJ; Nicolette CA; Margolis DM
    AIDS Res Hum Retroviruses; 2018 Jan; 34(1):111-122. PubMed ID: 28636433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Jacobson JM; Routy JP; Welles S; DeBenedette M; Tcherepanova I; Angel JB; Asmuth DM; Stein DK; Baril JG; McKellar M; Margolis DM; Trottier B; Wood K; Nicolette C
    J Acquir Immune Defic Syndr; 2016 May; 72(1):31-8. PubMed ID: 26751016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.
    Routy JP; Boulassel MR; Yassine-Diab B; Nicolette C; Healey D; Jain R; Landry C; Yegorov O; Tcherepanova I; Monesmith T; Finke L; Sékaly RP
    Clin Immunol; 2010 Feb; 134(2):140-7. PubMed ID: 19889582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection.
    Gay CL; Kuruc JD; Falcinelli SD; Warren JA; Reifeis SA; Kirchherr JL; James KS; Dewey MG; Helms A; Allard B; Stuelke E; Gamble A; Plachco A; Gorelick RJ; Eron JJ; Hudgens M; Garrido C; Goonetilleke N; DeBenedette MA; Tcherepanova IY; Nicolette CA; Archin NM; Margolis DM
    Sci Rep; 2020 Mar; 10(1):5134. PubMed ID: 32198428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.
    Li JZ; Heisey A; Ahmed H; Wang H; Zheng L; Carrington M; Wrin T; Schooley RT; Lederman MM; Kuritzkes DR;
    AIDS; 2014 Nov; 28(18):2649-57. PubMed ID: 25254301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of autologous dendritic cell-based immunotherapy (AGS-004) on B- and T-cell subset changes and immune activation in HIV-infected patients receiving antiretroviral therapy.
    Jenabian MA; Nicolette CA; Tcherepanova IY; Debenedette MA; Gilmore N; Routy JP
    J Acquir Immune Defic Syndr; 2013 Dec; 64(4):345-50. PubMed ID: 24025338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection.
    Yue FY; Cohen JC; Ho M; Rahman AKMN; Liu J; Mujib S; Saiyed A; Hundal S; Khozin A; Bonner P; Liu D; Benko E; Kovacs C; Ostrowski M
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption.
    de Goede AL; van Deutekom HW; Vrancken B; Schutten M; Allard SD; van Baalen CA; Osterhaus AD; Thielemans K; Aerts JL; Keşmir C; Lemey P; Gruters RA
    AIDS; 2013 Nov; 27(17):2679-89. PubMed ID: 24149085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.
    Papasavvas E; Foulkes A; Yin X; Joseph J; Ross B; Azzoni L; Kostman JR; Mounzer K; Shull J; Montaner LJ
    Immunology; 2015 Jul; 145(3):380-90. PubMed ID: 25684333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
    Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
    EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
    Leth S; Schleimann MH; Nissen SK; Højen JF; Olesen R; Graversen ME; Jørgensen S; Kjær AS; Denton PW; Mørk A; Sommerfelt MA; Krogsgaard K; Østergaard L; Rasmussen TA; Tolstrup M; Søgaard OS
    Lancet HIV; 2016 Oct; 3(10):e463-72. PubMed ID: 27658863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.
    Macatangay BJ; Riddler SA; Wheeler ND; Spindler J; Lawani M; Hong F; Buffo MJ; Whiteside TL; Kearney MF; Mellors JW; Rinaldo CR
    J Infect Dis; 2016 May; 213(9):1400-9. PubMed ID: 26647281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of CD57 and CD62L-CD45RA+ CD8 T lymphocytes correlates with reduced viral plasma RNA after primary HIV infection.
    Lieberman J; Trimble LA; Friedman RS; Lisziewicz J; Lori F; Shankar P; Jessen H
    AIDS; 1999 May; 13(8):891-9. PubMed ID: 10371169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
    Tebas P; Jadlowsky JK; Shaw PA; Tian L; Esparza E; Brennan AL; Kim S; Naing SY; Richardson MW; Vogel AN; Maldini CR; Kong H; Liu X; Lacey SF; Bauer AM; Mampe F; Richman LP; Lee G; Ando D; Levine BL; Porter DL; Zhao Y; Siegel DL; Bar KJ; June CH; Riley JL
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption.
    D'Offizi G; Montesano C; Agrati C; Gioia C; Amicosante M; Topino S; Narciso P; Pucillo LP; Ippolito G; Poccia F
    AIDS; 2002 Dec; 16(18):2431-8. PubMed ID: 12461417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.
    Crooks AM; Bateson R; Cope AB; Dahl NP; Griggs MK; Kuruc JD; Gay CL; Eron JJ; Margolis DM; Bosch RJ; Archin NM
    J Infect Dis; 2015 Nov; 212(9):1361-5. PubMed ID: 25877550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.